Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2016

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2016
Published Jun 30, 2016
1371 pages — Published Jun 30, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2016, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
- The report reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutics and enlists all their major and minor projects
- The report assesses Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
-

  
Source:
Document ID
GMDHC7960IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents250
  List of Tables447
  List of Figures511
Introduction521
  Global Markets Direct Report Coverage521
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview531
Therapeutics Development542
  Pipeline Products for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview541
  Pipeline Products for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Comparative Analysis551
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics under Development by Companies5617
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics under Investigation by Universities/Institutes733
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Pipeline Products Glance764
  Late Stage Products761
  Clinical Stage Products771
  Early Stage Products781
  Unknown Stage Products791
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Products under Development by Companies8030
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Products under Investigation by Universities/Institutes1104
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Companies Involved in Therapeutics Development114200
  4SC AG1141
  AB Science SA1151
  AbbVie Inc.1161
  Acetylon Pharmaceuticals, Inc.1171
  Actinium Pharmaceuticals, Inc.1181
  ADC Therapeutics Sarl1191
  Advenchen Laboratories, LLC1201
  Aeglea BioTherapeutics, Inc.1211
  Affichem SA1221
  Agios Pharmaceuticals, Inc.1231
  AIMM Therapeutics B.V.1241
  Akinion Pharmaceuticals AB1251
  Altor BioScience Corporation1261
  Amgen Inc.1271
  Antigen Express, Inc.1281
  Antisense Therapeutics Limited1291
  APIM Therapeutics AS1301
  Aprea AB1311
  arGEN-X BV1321
  Ariad Pharmaceuticals, Inc.1331
  Arno Therapeutics, Inc.1341
  Arog Pharmaceuticals, Inc.1351
  Array BioPharma Inc.1361
  Astellas Pharma Inc.1371
  Asterias Biotherapeutics, Inc.1381
  Astex Pharmaceuticals, Inc.1391
  AstraZeneca Plc1401
  Atara Biotherapeutics, Inc.1411
  Athenex, Inc.1421
  Aurigene Discovery Technologies Limited1431
  AVEO Pharmaceuticals, Inc.1441
  Bayer AG1451
  BCI Pharma1461
  Bellicum Pharmaceuticals, Inc.1471
  BerGenBio AS1481
  Bio-Cancer Treatment International Limited1491
  Bio-Path Holdings, Inc.1501
  BioInvent International AB1511
  BioLineRx, Ltd.1521
  BioSight Ltd.1531
  Blueprint Medicines Corporation1541
  Boehringer Ingelheim GmbH1551
  Boston Biomedical, Inc.1561
  Bristol-Myers Squibb Company1571
  Calithera Biosciences, Inc.1581
  Cancer Therapeutics CRC Pty Ltd1591
  Cantargia AB1601
  Cantex Pharmaceuticals, Inc.1611
  Cascadian Therapeutics Inc1621
  Celator Pharmaceuticals, Inc.1631
  Celgene Corporation1641
  Cellceutix Corporation1651
  Celldex Therapeutics, Inc.1661
  Cellectis S.A.1671
  Cellerant Therapeutics, Inc.1681
  Celyad SA1691
  CharlestonPharma LLC1701
  Constellation Pharmaceuticals, Inc.1711
  ConverGene, LLC1721
  Cornerstone Pharmaceuticals, Inc.1731
  Critical Outcome Technologies Inc.1741
  CrystalGenomics, Inc.1751
  CTI BioPharma Corp.1761
  Cyclacel Pharmaceuticals, Inc.1771
  Daiichi Sankyo Company, Limited1781
  DC Prime B.V.1791
  Debiopharm International SA1801
  Deciphera Pharmaceuticals, LLC1811
  DiNonA Inc.1821
  Eisai Co., Ltd.1831
  Eli Lilly and Company1841
  EntreChem, S.L.1851
  EpiZyme, Inc.1861
  Erytech Pharma SA1871
  Esperance Pharmaceuticals, Inc.1881
  Eureka Therapeutics, Inc.1891
  Exelixis, Inc.1901
  F. Hoffmann-La Roche Ltd.1911
  Fate Therapeutics, Inc.1921
  FORMA Therapeutics, Inc.1931
  Formula Pharmaceuticals, Inc.1941
  Fortress Biotech, Inc.1951
  Forty Seven Inc.1961
  Fujifilm Corporation1971
  Gadeta B.V.1981
  Galen Limited1991
  Gamida Cell Ltd.2001
  Genentech, Inc.2011
  Genoscience Pharma2021
  Genosco2031
  Genzyme Corporation2041
  Gilead Sciences, Inc.2051
  GlaxoSmithKline Plc2061
  GlycoMimetics, Inc.2071
  Golden Biotechnology Corp.2081
  H3 Biomedicine Inc.2091
  Hanmi Pharmaceuticals, Co. Ltd.2101
  HEC Pharm Co., Ltd.2111
  Huperion Sarl2121
  Hybrigenics S.A.2131
  Igenica Biotherapeutics, Inc.2141
  Ignyta, Inc.2151
  Immatics Biotechnologies GmbH2161
  Immune Pharmaceuticals Inc.2171
  Immune System Key Ltd.2181
  ImmunGene, Inc.2191
  ImmunoGen, Inc.2201
  Incyte Corporation2211
  Inflection Biosciences Limited2221
  Interprotein Corporation2231
  Jasco Pharmaceuticals, LLC.2241
  Jiangsu Hansoh Pharmaceutical Co., Ltd.2251
  Johnson &Johnson2261
  Juno Therapeutics Inc.2271
  JW Pharmaceutical Corporation2281
  Kainos Medicine, Inc.2291
  Karyopharm Therapeutics, Inc.2301
  Kiadis Pharma B.V.2311
  Kolltan Pharmaceuticals, Inc.2321
  Komipharm International Co., Ltd.2331
  Kyowa Hakko Kirin Co., Ltd.2341
  Lead Discovery Center GmbH2351
  Les Laboratoires Servier SAS2361
  MacroGenics, Inc.2371
  Mateon Therapeutics Inc2381
  MaxCyte, Inc.2391
  medac GmbH2401
  MediGene AG2411
  Medivation, Inc.2421
  MEI Pharma, Inc.2431
  Merck &Co., Inc.2441
  Merus B.V.2451
  Mesoblast Limited2461
  Millennium Pharmaceuticals, Inc.2471
  miRagen Therapeutics, Inc.2481
  Mirna Therapeutics, Inc.2491
  Moleculin Biotech, Inc.2501
  MolMed S.p.A.2511
  Nanovalent Pharmaceuticals Inc.2521
  NantKwest, Inc.2531
  Nemucore Medical Innovations, Inc.2541
  Nerviano Medical Sciences S.r.l.2551
  Neumedicines Inc.2561
  Novartis AG2571
  NuCana BioMed Limited2581
  Omeros Corporation2591
  OncoImmune, Inc.2601
  Onconova Therapeutics, Inc.2611
  Oncopeptides AB2621
  OncoTartis, Inc.2631
  OncoTherapy Science, Inc.2641
  Ono Pharmaceutical Co., Ltd.2651
  Otsuka Holdings Co., Ltd.2661
  Oxford BioTherapeutics Ltd2671
  Panther Biotechnology, Inc.2681
  Pfizer Inc.2691
  Pharma Mar, S.A.2701
  Pharmedartis GmbH2711
  Philogen S.p.A.2721
  Phylogica Limited2731
  Plexxikon Inc.2741
  Polaris Pharmaceuticals, Inc.2751
  Polyphor Ltd.2761
  Resverlogix Corp.2771
  Rich Pharmaceuticals, Inc.2781
  Sanofi2791
  Sareum Holdings Plc2801
  Seattle Genetics, Inc.2811
  Sellas Inc.2821
  Selvita S.A.2831
  Senhwa Biosciences, Inc.2841
  Shire Plc2851
  SialoTec GmbH2861
  Sigma-Tau S.p.A.2871
  SOM Innovation Biotech SL2881
  Sorrento Therapeutics, Inc.2891
  Stemline Therapeutics, Inc.2901
  Sumitomo Dainippon Pharma Co., Ltd.2911
  Sunesis Pharmaceuticals, Inc.2921
  Syndax Pharmaceuticals, Inc.2931
  SYNIMMUNE GmbH2941
  Synta Pharmaceuticals Corp.2951
  Syros Pharmaceuticals, Inc.2961
  TaiGen Biotechnology Co., Ltd.2971
  Takeda Pharmaceutical Company Limited2981
  Targazyme, Inc.2991
  TetraLogic Pharmaceuticals3001
  Teva Pharmaceutical Industries Ltd.3011
  Theravectys SA3021
  Toko Pharmaceutical Industries Co., Ltd.3031
  Tolero Pharmaceuticals, Inc.3041
  Tragara Pharmaceuticals, Inc.3051
  Trillium Therapeutics Inc.3061
  Verastem, Inc.3071
  Vichem Chemie Research Ltd.3081
  VioQuest Pharmaceuticals, Inc.3091
  Viralytics Ltd.3101
  Xencor, Inc.3111
  Xenetic Biosciences (UK) Limited3121
  ZIOPHARM Oncology, Inc.3131
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Assessment31453
  Assessment by Monotherapy Products3141
  Assessment by Combination Products3151
  Assessment by Target31623
  Assessment by Mechanism of Action33924
  Assessment by Route of Administration3632
  Assessment by Molecule Type3652
Drug Profiles3671005
  (cytarabine hydrochloride + daunorubicin hydrochloride) Drug Profile36711
  1D-11 Drug Profile3781
  1J-373 Drug Profile3791
  4EGI-1 Drug Profile3801
  4G8-SDIEM Drug Profile3811
  4SC-202 Drug Profile3823
  AAG-344 Drug Profile3851
  AAG-366 Drug Profile3861
  ABBV-075 Drug Profile3871
  ACT-001 Drug Profile3881
  Actimab-A Drug Profile3896
  ACY-957 Drug Profile3952
  adarotene Drug Profile3971
  ADCT-301 Drug Profile3981
  AEB-1102 Drug Profile3992
  AF-122 Drug Profile4011
  AG-120 Drug Profile4025
  AG-881 Drug Profile4071
  AGI-14100 Drug Profile4081
  AGS-67E Drug Profile4091
  AKN-032 Drug Profile4101
  AL-8326 Drug Profile4111
  alpelisib Drug Profile4123

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acute-Myelocytic-Leukemia-AML-Acute-Myeloblastic-Leukemia-Pipeline-Review-H1-2016-2088-16064>
  
APA:
Global Markets Direct - Market Research. (2016). Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acute-Myelocytic-Leukemia-AML-Acute-Myeloblastic-Leukemia-Pipeline-Review-H1-2016-2088-16064>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.